Pilot Study of a Dietary Intervention to Prevent Acne Recurrence

NCT ID: NCT00132574

Last Updated: 2006-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether minimizing the intake of milk and dairy products will reduce the recurrence of acne among people who have been successfully treated for acne with isotretinoin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acne is one of the most common dermatologic diseases affecting 40 to 50 million people in the United States, most of who are adolescents and young adults. In addition to the well-recognized physical sequelae of this condition, several studies have linked severe acne to considerable social impairments and serious psychological conditions including suicidal ideation and major depression. Furthermore, severe acne has been recognized in some studies as a risk factor for breast cancer, suggesting that these conditions may have common causes. Little is known about the role of diet in the pathogenesis of acne. Recent analyses of the Nurses' Health Study II and the Growing-Up Today Study suggest that high intake of milk increases the risk of developing acne during adolescence. Despite the consistency of findings between these two studies, they cannot be regarded as conclusive and further research is needed in this area. Establishing the nature of the association between milk intake and acne can have broad clinical and public health implications. It could enhance the currently existing therapeutic options for the treatment of acne. More importantly, public health recommendations regarding milk and dairy intake could be designed in order to prevent its effects on the sebaceous glands and probably other hormone sensitive glands like the breast.

To test the hypothesis that milk intake increases the risk of developing acne, we will compare the effect of minimizing milk and dairy intake against not making changes in the diet of subjects who usually consume at least 2 servings/day of milk and dairy products on the recurrence of acne lesions among patients previously treated with isotretinoin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

acne, dairy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minimization of milk and dairy products in the diet

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 16 and 25 years of age who have successfully completed treatment for acne with oral isotretinoin.
* Patients who regularly consume at least 2 servings (480ml) of milk per day.
* Patients who can attend scheduled study follow-up visits at the Leeds General Infirmary.
* Patients who grant informed consent for participation in the study.
* Patients who agree to comply with the intervention and follow-up procedures in the study.

Exclusion Criteria

* Patients who received isotretinoin for a condition other than acne (e.g Malassezia folliculitis).
* Patients who have been off isotretinoin for more than 60 days at the moment of enrolment into the study.
* Patients who used any topical or oral acne medications between the end of therapy with isotretinoin and enrolment in the study.
* Patients who have been previously diagnosed with an endocrinologic disorder likely to cause acne such as polycystic ovary syndrome, congenital adrenal hyperplasia, adrenal or ovarian tumors or any other hyperandrogenemic states.
* Patients who are using any of the following medications which are likely to cause or abate acne:

* Corticosteroids;
* Contraceptives containing medroxyprogesterone acetate, norgestrel or levonorgestrel;
* Dilantin or other antiepileptic;
* Finasteride, spironolactone or flutamide;
* Testosterone or dietary body-building protein powders.
Minimum Eligible Age

16 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Department of Dermatology, Leeds General Infirmary

UNKNOWN

Sponsor Role collaborator

Breast Cancer Research Foundation

OTHER

Sponsor Role collaborator

Harvard School of Public Health (HSPH)

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Walter C Willett, MD, DrPH

Role: PRINCIPAL_INVESTIGATOR

Harvard School of Public Health (HSPH)

Jorge E Chavarro, MD, SM

Role: STUDY_DIRECTOR

Harvard School of Public Health (HSPH)

F. William Danby, MD, FRCPC

Role: STUDY_DIRECTOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Dermatology, Leeds General Infirmary

Leeds, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SRC200402

Identifier Type: -

Identifier Source: secondary_id

BCRF-P11733

Identifier Type: -

Identifier Source: org_study_id